Physician profile
Mark E Murphy
NPI 1396725628
$2,622.35
in general payments reported to CMS, 2019-2025
25 companies · $581 in 2025
The $581 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $168 · 2021: $368 · 2022: $594 · 2023: $413 · 2024: $278 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,082.29 | 2019-2025 | |
| Pfizer INC. | $298.99 | 2019-2025 | |
| Janssen Biotech, INC. | $230.80 | 2019-2024 | Stelara, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $130.16 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.78 | 2020-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $91.48 | 2021-2025 | Gattex, Entyvio |
| Celgene Corporation | $84.76 | 2021-2023 | |
| Boston Scientific Corporation | $78.51 | 2021-2024 | |
| Allergan, INC. | $64.91 | 2019 | |
| Genzyme Corporation | $58.68 | 2024-2025 | |
| Ardelyx, INC. | $47.27 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $44.89 | 2022-2025 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $44.55 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $36.58 | 2023-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $36.16 | 2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $27.58 | 2024 | Sucraid |
| Alnylam Pharmaceuticals INC. | $23.04 | 2025 | Givlaari |
| Organon LLC | $22.94 | 2025 | Hadlima, Renflexis |
| Mallinckrodt Hospital Products INC. | $19.98 | 2025 | Terlivaz |
| Amgen INC. | $17.85 | 2023 | Amjevita, Avsola |
| Redhill Biopharma INC. | $16.05 | 2021 | |
| Ucb, INC. | $15.79 | 2019 | |
| Lilly USA, LLC | $15.26 | 2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $11.04 | 2021 | |
| Endogastric Solutions, INC | $6.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.